British HIV Association guidelines for antiretroviral treatment of HIV‐2‐positive individuals 2010 (Q44214722)

reason for preferred rank

30 November 2017

title

British HIV Association guidelines for antiretroviral treatment of HIV‐2‐positive individuals 2010 (English)

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

6 August 2024

British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20961377

6 August 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20961377

6 August 2024

J Anderson

9

0 references

Yvonne Gilleece

object named as

Y Gilleece

1

0 references

author name string

BHIVA Guidelines Subcommittee

10

1 reference

30 November 2017

D. R. Chadwick

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20961377

6 August 2024

J. Breuer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20961377

6 August 2024

D. Hawkins

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20961377

6 August 2024

E. Smit

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20961377

6 August 2024

L. X. McCrae

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20961377

6 August 2024

D. Pillay

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20961377

6 August 2024

N. Smith

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20961377

6 August 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20961377

6 August 2024

publication date

1 November 2010

1 reference

full work available at URL

30 November 2017

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1468-1293.2010.00889.x

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20961377

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1468-1293.2010.00889.x

6 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1468-1293.2010.00889.x

6 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

6 August 2024

1 reference

30 November 2017

volume

11

1 reference

30 November 2017

issue

10

1 reference

30 November 2017

page(s)

611-619

1 reference

Rate of decline of percentage CD4+ cells is faster in HIV-1 than in HIV-2 infection

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2010.00889.X

Prevalence and incidence of HIV-1 and HIV-2 before, during and after a civil war in an occupational cohort in Guinea-Bissau, West Africa.

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Prevalence of HIV-2 infection in Europe.

6 August 2024

3

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

The global distribution of human immunodeficiency virus type 2 (HIV-2) infection

6 August 2024

6

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Slower heterosexual spread of HIV-2 than HIV-1.

6 August 2024

7

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast

6 August 2024

8

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

AIDS following mother-to-child transmission of HIV-2.

6 August 2024

9

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Vertical transmission of HIV-2

6 August 2024

10

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Differences in proviral DNA load between HIV-1- and HIV-2-infected patients

6 August 2024

11

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Association between HIV-2 infection and genital ulcer diseases among male sexually transmitted disease patients in The Gambia

6 August 2024

13

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Epidemiological characteristics of human immunodeficiency virus type-2 infection in Africa

6 August 2024

14

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Reduced rate of disease development after HIV-2 infection as compared to HIV-1

6 August 2024

16

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

HIV-2-infected patients survive longer than HIV-1-infected patients.

6 August 2024

18

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia

6 August 2024

19

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Low level viremia and high CD4% predict normal survival in a cohort of HIV type-2-infected villagers

6 August 2024

20

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection

6 August 2024

22

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal

6 August 2024

23

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Chronic HIV-2 infection protects against total CD4+ cell depletion and rapid disease progression induced by SHIV89.6p challenge

6 August 2024

24

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Dual infections with HIV-1, HIV-2 and HTLV-I are more common in older women than in men in Guinea-Bissau.

6 August 2024

25

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Differences in HIV-2 plasma viral load and immune activation in HIV-1 and HIV-2 dually infected persons and those infected with HIV-2 only in Abidjan, Côte D'Ivoire.

6 August 2024

26

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Virological and polymerase chain reaction studies of HIV-1/HIV-2 dual infection in Côte d'Ivoire

6 August 2024

27

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Plasma RNA viral load predicts the rate of CD4 T cell decline and death in HIV-2-infected patients in West Africa

6 August 2024

32

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Antiretroviral therapy for HIV-2 infected patients.

6 August 2024

33

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France

6 August 2024

34

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients.

6 August 2024

36

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay

6 August 2024

38

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.

6 August 2024

39

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy

6 August 2024

42

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy

6 August 2024

44

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance

6 August 2024

45

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen

6 August 2024

46

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2

6 August 2024

47

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues

6 August 2024

49

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2.

6 August 2024

50

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries

6 August 2024

51

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Introduction of HIV drug-resistance testing in clinical practice

6 August 2024

52

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors

6 August 2024

53

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors

6 August 2024

55

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.

6 August 2024

56

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy

6 August 2024

58

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia

6 August 2024

60

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Highly active antiretroviral therapy and viral response in HIV type 2 infection

6 August 2024

61

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients

6 August 2024

62

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART.

6 August 2024

63

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy

6 August 2024

64

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance

6 August 2024

65

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir

6 August 2024

66

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

6 August 2024

67

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro

6 August 2024

69

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients

6 August 2024

70

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry

6 August 2024

72

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.

6 August 2024

74

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients

6 August 2024

75

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings

6 August 2024

76

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

Antiretroviral therapy in patients with dual infection with human immunodeficiency virus types 1 and 2.

6 August 2024

78

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008

6 August 2024

79

1 reference

https://api.crossref.org/works/10.1111/J.1468-1293.2010.00889.X

6 August 2024

Identifiers

1 reference

30 November 2017

1 reference